
Immuno‐oncology (IO) drugs are an essential treatment option for BRAF wild‐type melanoma. However, effective treatment for IO drug‐resistant BRAF wild‐type melanoma is yet to be established. The proportion of BRAF wild‐type melanoma is known to be higher in acral lentiginous melanoma (ALM) and mucosal melanoma (MCM) than in other clinical subtypes.1 Consequently, treatment options other than IO drugs have important implications for these clinical subtypes. Several studies have reported that the response rate (RR) of chemotherapy increases after IO drugs administration;2–4 however, no study has reported an improvement in survival analysis.
Like
Save
Share